Please Note:
This profile was automatically generated using 1 reference found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 1 reference found on the Internet. This information has not been verified. Learn more...
Web References
-
1. Quest 2
www.mefmaction.net/Home/Newsle - [Cached]Published on: 10/2/1993 Last Visited: 11/19/2007
CANADA - In reply to my letter of September 1, 1993 to Health & Welfare Canada, Health Protection Branch, regarding the status of Ampligen, Jacques Bouchard, Ph.D. in his letter of September 30th advised the following:
...
The Sponsor, however, is not required to inform the Health Protection Branch when implementation of protocols is delayed or notify us when clinical trials are not implemented due to administrative reasons.Signed: Jacques Bouchard, Ph.D. A/Chief, Aids & Viral Diseases Division, Bureau of Human Prescription Drugs"
